Loading data for CLDI — first visit, this takes a few seconds.
Calidi Biotherapeutics In... (CLDI)
NYSE American: CLDI
· Precio en tiempo real · USD
1.27
-0.09 (-6.62%)
Al cierre: Aug 18, 2026, 3:58 PM
1.24
-4.98%
Premercado: 4:02 AM
Calidi Biotherapeutics Inc. (CLDI) Stock Price, Analysis & Data
-6.62% (1D)
| Precio de compra | n/a |
| Capitalización de mercado | 3.11M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -23.45M |
| Beta | n/a |
| EPS (TTM) | -62.3 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -1.41 |
| P/B (TTM) | 0.57 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | n/a |
| Volumen | 129,797 |
| Volumen medio (20D) | 325,409 |
| Abierto | 1.32 |
| Anterior Cerrar | 1.36 |
| Rango del día | 1.25 - 1.33 |
| Rango de 52 semanas | 1.25 - 30.40 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de CLDI
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-40...
Industria Biotechnology
Sector Healthcare
IPO Fecha Nov 1, 2021
Empleados 29
Bolsa de Valores NYSE American
Símbolo bursátil CLDI
Sitio web https://www.calidibio.com
Desempeño financiero
En 2025, los ingresos de Calidi Biotherapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -19.91M, una disminución de -10.1%.
Estados financierosSorpresa de resultados
Calidi Biotherapeutics ha publicado sus resultados trimestrales en Nov 13, 2025: